Stock Information
Ocular Therapeutix Inc (OCUL)
Ticker Symbol: OCUL
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $1,808.77 mil
Piotroski score: 3
PE Ratio: N/A
EPS (TTM): -1.4385
Revenue (TTM): $0.23 M
Dividend Yield: N/A%
ROE: -71.66%
Latest News
-
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial
Fri, May 1, 2026 9:20 AM
-
Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD
Thu, Apr 30, 2026 6:28 AM
-
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL)
Thu, Apr 30, 2026 2:08 AM
-
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data
Wed, Apr 29, 2026 1:17 PM
-
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Wed, Apr 29, 2026 11:00 AM
-
Ocular Therapeutix Enrolls First Patient In SOL-X Long-term Extension Trial For Axpaxli (Also Known As OTX-TKI) For Wet Age-related Macular Degeneration
Wed, Apr 29, 2026 7:17 AM
-
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Tue, Apr 28, 2026 11:00 AM
-
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Tue, Apr 28, 2026 2:02 AM
-
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Mon, Apr 27, 2026 11:00 AM
Key Financials
Financial data not available
